Table 2.
Clinical and Morphological Findings in 27 Cases of LCPT with MGUS.
| Reference | EM inclusions | Monoclonal Ig | Treatment | Follow (months) | Renal outcomes | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| (10) | No date | κ | C | 39 | Stable | |||||
| No date | κ | No treatment | 12 | Stable | ||||||
| (11) | Rhomboid, needle | κ | No treatment | 6 | Worsening | |||||
| (12) | No date | κ | No treatment | 24 | Stable | |||||
| (13) | No date | κ | No treatment | 42 | Worsening | |||||
| (7) | Geometric outlines (Noncrystal) | λ | No treatment | 24 | Stable | |||||
| (5) | Crystal | IgAκ | No treatment | 12 | Stable | |||||
| Crystal | IgGκ | No treatment | 72 | Hemodialysis | ||||||
| Noncrystal | κ | No treatment | 72 | Worsening | ||||||
| (14) | Needle, rectangular, rod | IgGκ | L, D | 4 | Improved | |||||
| (2) | Rhomboid | IgAκ | No treatment | 70 | Hemodialysis | |||||
| Rhomboid, lattice | IgGκ | No treatment | 18 | Hemodialysis, died | ||||||
| Rhomboid | Negative | B, D | 39 | Stable, progressed to MM | ||||||
| Rhomboid | κ | D | 19 | Died | ||||||
| Rhomboid | κ | SCT, M | 57 | Improved | ||||||
| Rhomboid | IgGκ | B, D | 39 | Stable | ||||||
| Rhomboid | κ | B | 36 | Worsening | ||||||
| Rhomboid | κ | SCT, L, B, D, M | 14 | Stable | ||||||
| Rhomboid | κ | T, B | 69 | Worsening | ||||||
| Rhomboid | κ | C, B, D | 5 | Stable | ||||||
| Rhomboid | κ | No treatment | 1 | Died | ||||||
| Rhomboid | κ | T | 49 | Improved | ||||||
| (15) | Rhomboid, rod | IgGκ | C, B, D→L, D | 12 | Stable | |||||
| (16) | Club | IgGκ | B, D | 30 | Improved | |||||
| (17) | Needle | IgGκ | C, B, D | 36 | Hemodialysis, progressed to MM | |||||
| (18) | Needle | κ | B, L, D | 12 | Improved | |||||
| (19) | Needle | IgGκ | No treatment | 12 | Stable |
EM: electron microscopy, SCT: stem cell transplantation, C: cyclophosphamide, L: lenalidomide, D: dexamethasone, B: bortezomib, M: melphalan, T: thalidomide